beta 3 ADRENERGIC AGONISTS

The present invention relates to a beta 3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity. La présente invention concern...

Full description

Saved in:
Bibliographic Details
Main Authors EVERS, BRITTA, RUEHTER, GERD, SPINAZZE, PATRICK, GIANPIETRO, FINLEY, DON, RICHARD, BASTIAN, JOLIE, ANNE, STEVENS, FREDDIE, CRAIG, TRANKLE, WILLIAM, GEORGE, JESUDASON, CYNTHIA, DARSHINI, KARANJAWALA, RUSHAD, E, WERNER, JOHN, ARNOLD, RATZ, ANDREW, MICHAEL, ROCCO, VINCENT, PATRICK, HE, JOHN, XIAOQIANG, SALL, DANIEL, JON, SCHOTTEN, THEO
Format Patent
LanguageEnglish
French
Published 27.02.2003
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a beta 3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity. La présente invention concerne un agoniste de récepteur beta 3 adrénergique correspondant à la formule (I); ou un sel pharmaceutiquement acceptable de celui-ci, capable d'augmenter la lipolyse et le transport d'énergie dans les cellules; de ce fait, il est utile pour traiter le diabète type 2 et/ou l'obésité.
Bibliography:Application Number: WO2002US21317